title: Heavily glycosylated, highly fit SIVMne variants continue to diversify and undergo selection after transmission to a new host and they elicit early antibody dependent cellular responses but delayed neutralizing antibody responses.
abstract: BACKGROUND
  Lentiviruses such as human and simian immunodeficiency viruses (HIV and SIV) undergo continual evolution in the host. Previous studies showed that the late-stage variants of SIV that evolve in one host replicate to significantly higher levels when transmitted to a new host. However, it is unknown whether HIVs or SIVs that have higher replication fitness are more genetically stable upon transmission to a new host. To begin to address this, we analyzed the envelope sequence variation of viruses that evolved in animals infected with variants of SIVMne that had been cloned from an index animal at different stages of infection.
  
  
  RESULTS
  We found that there was more evolution of envelope sequences from animals infected with the late-stage, highly replicating variants than in animals infected with the early-stage, lower replicating variant, despite the fact that the late virus had already diversified considerably from the early virus in the first host, prior to transmission. Many of the changes led to the addition or shift in potential-glycosylation sites-, and surprisingly, these changes emerged in some cases prior to the detection of neutralizing antibody responses, suggesting that other selection mechanisms may be important in driving virus evolution. Interestingly, these changes occurred after the development of antibody whose anti-viral function is dependent on Fc-Fcgamma receptor interactions.
  
  
  CONCLUSIONS
  SIV variants that had achieved high replication fitness and escape from neutralizing antibodies in one host continued to evolve upon transmission to a new host. Selection for viral variants with glycosylation and other envelope changes may have been driven by both neutralizing and Fcgamma receptor-mediated antibody activities.
authors.affiliation: Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. dke2002@cornell.edu
authors.forename: Dawnnica
authors.initials: D
authors.lastname: Eastman
authors.forename: Anne
authors.initials: A
authors.lastname: Piantadosi
authors.forename: Xueling
authors.initials: X
authors.lastname: Wu
authors.forename: Donald N
authors.initials: DN
authors.lastname: Forthal
authors.forename: Gary
authors.initials: G
authors.lastname: Landucci
authors.forename: Jason T
authors.initials: JT
authors.lastname: Kimata
authors.forename: Julie
authors.initials: J
authors.lastname: Overbaugh
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000917:Antibody Formation; D019143:Evolution, Molecular; D014644:Genetic Variation; D006031:Glycosylation; D000882:Haplorhini; D007111:Immunity, Cellular; D008969:Molecular Sequence Data; D010802:Phylogeny; D012641:Selection, Genetic; D016415:Sequence Alignment; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000635:transmission* / Q000821:virology; D015302:Simian Immunodeficiency Virus / Q000145:classification / Q000235:genetics* / Q000276:immunology* / Q000378:metabolism; D014759:Viral Envelope Proteins / Q000737:chemistry / Q000235:genetics* / Q000276:immunology / Q000378:metabolism
chemical_list: D000914:Antibodies, Viral; D014759:Viral Envelope Proteins